MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
The molecular genetics of Barrett's esophagus (BE) and its evolution to esophageal adenocarcinoma (EAC) have been widely studied; however, the molecular mechanism of BE-EAC carcinogenesis has not been completely understood. MicroRNA (miRNA) is now essential to understand the molecular mechanism of cancer progression. Recent findings include the following: firstly, miRNA expression profiles can distinguish between BE and EAC; secondly, miR-196a is upregulated in EAC tissues targeting annexin A1, thereby exerting antiapoptotic effects and contributing to EAC cell survival; miR-196a may also constitute a good biomarker of progression during BE-EAC carcinogenesis; and thirdly, The miR-106b-25 polycistron is activated by genomic amplification and is involved in esophageal neoplastic progression and proliferation via the suppression of two target genes, p21 and Bim.
Kan
Takatsugu
T
Department of Surgery, Kyoto University Hospital, Shogoin, Kyoto City, Japan. tsugu@kuhp.kyoto-u.ac.jp
Meltzer
Stephen J
SJ
D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D001471:Barrett Esophagus / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis / Q000145:classification / Q000378:metabolism* / Q000627:therapeutic use*; D008957:Models, Genetic; D011230:Precancerous Conditions / Q000235:genetics* / Q000378:metabolism / Q000628:therapy
D035683:MicroRNAs